The DOI matches its Crossref record.
Intravenous Gammaglobulin (IVIG): A Novel Approach to Improve Transplant Rates and Outcomes in Highly HLA-Sensitized Patients
Open accessAbstract
Intravenous immunoglobulin (IVIG) products are derived from pooled human plasma and have been used for the treatment of primary immunodeficiency disorders for more than 24 years. Shortly after their introduction, IVIG products were also found to be effective in the treatment of autoimmune and inflammatory disorders. Over the past 2 decades, the list of diseases where IVIG has a demonstrable beneficial effect has grown rapidly. These include Kawasaki disease, Guillain-Barre syndrome, myasthenia gravis, dermatomyositis and demyelinating polyneuropathy. Recently, we have described a beneficial effect on the reduction of anti-HLA antibodies with subsequent improvement in transplantation of highly HLA-sensitized patients as well as a potent anti-inflammatory effect that is beneficial in the treatment of antibody-mediated rejection (AMR). These advancements have enabled transplantation of patients previously considered untransplantable. These studies and relevant mechanism(s) of action will be discussed here.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Rituximab and Intravenous Immune Globulin for Desensitization during Renal Transplantation
Vo, A. A., Lukovsky, M., Toyoda, M., Wang, J., Reinsmoen, N. L., Lai, C.-H., Peng, A., Villicana, R., & Jordan, S. C. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0707894 · Cited by 692
Self-citationBanff 2011 Meeting Report: New Concepts in Antibody-Mediated Rejection
Mengel, M., Sis, B., Haas, M., Colvin, R. B., Halloran, P. F., Racusen, L. C., Solez, K., Cendales, L., Demetris, A. J., Drachenberg, C. B., et al. (2012) · American Journal of Transplantation · doi:10.1111/j.1600-6143.2011.03926.x · Cited by 399
Bortezomib Provides Effective Therapy for Antibody- and Cell-Mediated Acute Rejection
Everly, M. J., Everly, J. J., Susskind, B., Brailey, P., Arend, L. J., Alloway, R. R., Roy-Chaudhury, P., Govil, A., Mogilishetty, G., Rike, A. H., et al. (2008) · Transplantation · doi:10.1097/tp.0b013e318190af83 · Cited by 392
Activation of natural regulatory T cells by IgG Fc–derived peptide “Tregitopes”
De Groot, A. S., Moise, L., McMurry, J. A., Wambre, E., Van Overtvelt, L., Moingeon, P., Scott, D. W., & Martin, W. (2008) · Blood · doi:10.1182/blood-2008-02-138073 · Cited by 392
Reduced Binding of Human Antibodies to Cells From GGTA1/CMAH KO Pigs
Burlak, C., Paris, L. L., Lutz, A. J., Sidner, R. A., Estrada, J., Li, P., Tector, M., & Tector, A. J. (2014) · American Journal of Transplantation · doi:10.1111/ajt.12744 · Cited by 87
Metadata
- Authors
- Jordan, S. C., Vo, A. A., Peng, A., Toyoda, M., & Tyan, D.
- Venue
- American Journal of Transplantation
- Publisher
- Elsevier BV
- Published
- 2006-03
- Volume
- 6
- Issue
- 3
- Pages
- 459-466
- ISSN
- 1600-6135 (ISSN-L)
- OpenAlex
- W2003798082
- Cited by
- 180
- References
- 0
- FWCI
- 16.30
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Intravenous Gammaglobulin (IVIG): A Novel Approach to Improve Transplant Rates and Outcomes in Highly HLA-Sensitized Patients. https://app.cochat.ai/papers/10.1111/j.1600-6143.2005.01214.x
- The paper
- Jordan, S. C., Vo, A. A., Peng, A., Toyoda, M., & Tyan, D. (2006). Intravenous Gammaglobulin (IVIG): A Novel Approach to Improve Transplant Rates and Outcomes in Highly HLA-Sensitized Patients. American Journal of Transplantation. https://doi.org/10.1111/j.1600-6143.2005.01214.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.